Research Article

The Effect of Antivascular Endothelial Growth Factor on the Development of Adhesion Formation in Laparotomized Rats: Experimental Study

Murat Basbug,1 Nurullah Bulbuler,2 Cemalettin Camci,2 Refik Ayten,2 Erhan Aygen,2 Ibrahim Hanifi Ozercan,3 Zulfu Arikanoglu,1 and Sami Akbulut1

1 Department of General Surgery, Diyarbakir Education and Research Hospital, 21400 Diyarbakir, Turkey
2 Department of General Surgery, Faculty of Medicine, Firat University, 23100 Elazig, Turkey
3 Department of Medical Pathology, Faculty of Medicine, Firat University, 23100 Elazig, Turkey

Correspondence should be addressed to Sami Akbulut, akbulutsami@gmail.com

Received 16 February 2011; Accepted 2 May 2011

Academic Editor: Hirozumi Sawai

Copyright © 2011 Murat Basbug et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Aims. This study determined the effects of a single dose of bevacizumab, an antiangiogenic recombinant monoclonal antibody that specifically targets vascular endothelial growth factor (VEGF), on adhesion formation in the rat cecal abrasion model. Methodology. Thirty female Wistar albino rats (200–224 g) were divided into three groups. All rats underwent laparotomy at which time cecal wall abrasion and abdominal wall injuries were induced. Group I (control) underwent only the abrasion procedure; Groups II and III received saline or bevacizumab intraperitoneally, respectively, following the abrasion. The rats were killed on postoperative day 7, and the severity of adhesions was evaluated, together with histopathological fibrosis parameters and immunohistochemical staining to identify the VEGF receptor. Results. The mean adhesion severity score in Groups I–III was 2.5 ± 0.52, 2.4 ± 0.69, and 0.7 ± 0.82, respectively; the score in Group III was significantly lower than that in Groups I (P < 0.001) and II (P < 0.001). In the histopathological evaluation, the mean fibrosis score in Group III was significantly lower than in Groups I (P < 0.001) and II (P < 0.001). VEGF staining of the adhesion areas in Group III was significantly lower than that in Groups I (P < 0.001) and II (P < 0.001). Conclusion. Bevacizumab decreases adhesion formation following laparotomy in rats by blocking VEGF receptor occupancy.

1. Introduction

Postoperative adhesion formation is a major clinical problem in patients who undergo abdominal surgery [1,2]. Peritoneal adhesions are defined as pathological fibrotic bands that develop between any surfaces in the peritoneal cavity [2]. These adhesions can be induced by infection, inflammation, ischemia, and surgical injury and are the leading cause of pelvic pain, infertility, and bowel obstruction. The mechanisms underlying the predisposition to form adhesions and their site specificity are unknown [2–4]. Intra-abdominal adhesions are believed to develop as a result of ischemia and trauma to the serosal surface of bowel or peritoneum [4–6]. After peritoneal injury, vascular permeability is increased in vessels supplying the damaged area; this is followed by an exudation of inflammatory cells ultimately leading to the formation of fibrin matrix, which connects two injured peritoneal surfaces forming fibrin bands [6,7].

Following fibrin band formation, fibrinolysis breaks the bands into smaller molecules as fibrin degradation products [7,8]. If the fibrinolysis system is depressed, the adhesions are not lysed completely and the fibrin bands persist [8]. The tissue forming the adhesions is a mixture of macrophages, red blood cells, fibroblasts, nerve fibers, and small vascular channels of endothelial cells. Macrophages play an important role in this condition as they synthesize and release growth factor, which is mitogenic, chemotactic, and angiogenic [1,9].

Angiogenesis, the process of developing new blood vessels, is a fundamental process in inflammation and wound repair. Angiogenesis is turned on or off by regulatory factors located in the extracellular matrix, which acts as a reservoir...


of factors that can be released after wounding or under other physiological conditions [10]. Human peritoneal capillaries and arteriole endothelial cells express vascular endothelial growth factor (VEGF) and angiogenic factors that regulate the proteolytic enzymes and their inhibitors.

Since VEGF plays a key role in coagulation, fibrinolytic, and angiogenic activities, it is considered a critical cytokine in the development of peritoneal adhesions [1, 10, 11]. We hypothesized that the angiogenesis inhibitor bevacizumab can reduce peritoneal adhesions by increasing VEGF levels and investigated the effects of bevacizumab on intraperitoneal adhesions.

2. Materials and Methods

2.1. Protocol. This study was conducted in the Experimental Animal Raising and Research Laboratory of Fırat University, Faculty of Medicine, Elazığ, Turkey, after the approval of the local ethics committee. All experimental manipulations were in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.

2.2. Animals. Thirty female Wistar albino rats (11–12 weeks of age, weighing 200–224 g) were acclimatized for 1 week before the experiments. The animals were kept in individual cages, housed at constant room temperature, and given standard rat chow. Only water was provided in the 12 h preceding the experiments.

2.3. Experimental Groups. The rats were divided randomly into three groups by block randomization using Random Allocation Software ver. 1.00. The researchers were blinded to the treatment, saline, and control groups. In Group I (control), abrasion only was performed. In Group II, abrasion was performed and 0.9% NaCl was administered intraperitoneally. In Group III, abrasion was performed and 2.5 mg/kg bevacizumab (Avastin, 25 mg/mL, Roche, Basel, Switzerland) was administered intraperitoneally.

2.4. Experimental Design. All rats were anesthetized with a combination of 5 mg/kg intramuscular xylazine (Bayer, Istanbul, Turkey) and 30 mg/kg ketamine hydrochloride (Parke-Davis, Istanbul, Turkey). All animals breathed spontaneously throughout the procedures. The mid-abdominal area was shaved and prepared with povidone-iodine as antisepic. A 3 cm midline incision was made and the cecum was exteriorized. A 1-2 cm² area of the cecum was brushed eight to ten times with a gauze bandage, and then a 1 cm² peritoneal injury on the right abdominal wall opposite to the cecum was also produced by brushing. The abdominal incision was closed with continuous 3-0 silk sutures. Only water was given to all of the animals on the first postoperative day; standard rat chow and water were provided on the succeeding days.

On postoperative day 7, the rats were anesthetized as previously described and a repeat laparotomy was performed with a reversed U-shaped incision of the anterior abdominal wall, which was retracted caudally to provide maximal exposure, without damaging the area in which the abrasion had been performed.

2.5. Adhesion Assessment and the Adhesion Severity Score. Adhesions were assessed between organs and the abdominal wall and among the organs themselves. Two surgeons blinded to the study (not members of the surgical team) scored the adhesions separately, and a consensus score was obtained for each rat. The type of adhesions was scored according to the method of Evans et al. [12], in which Grade 0 indicates no adhesions, Grade I indicates adhesions separating spontaneously, Grade II indicated adhesions separating by traction, and Grade III indicates adhesions separating with sharp dissection (Table 1, Figures 1(a)–1(d)).

2.6. Fibrosis Score. The adhesions were excised with the adhesion surfaces, and the resected adhesion specimens were fixed in formaldehyde. After dehydration, they were embedded in paraffin. Then, 5 mm cross-sections were prepared, stained with hematoxylin and eosin (H&E), and evaluated under a light microscope at a magnification of ×100. The adhesions were categorized as histopathological Grades 0–III based on the presence and extent of fibrosis [1, 4–6]. All evaluations were performed by an experienced pathologist who was blinded to the groups. Grade 0 was defined as no fibrosis, Grade I as slight fibrosis, Grade II as intermediate fibrosis, and Grade III as severe fibrosis (Table 2).

2.7. Immunohistochemical (IHC) Staining Procedure. The adhesions were excised with the adhesion surfaces. The adhesion tissue was placed in 10% formaldehyde for both VEGF (NeoMarkers, ready to use; Neomarkers Inc., Fremont, CA, USA) receptor level measurements and IHC analysis. After few hours in fixative, the biopsy specimens were embedded in

---

**Table 1: Definitions of the grades of peritoneal adhesions according to Evans.**

| Grade | Definitions of severity grades of the peritoneal adhesions according to Evans model |
|-------|-----------------------------------------------------------------------------------|
| 0     | No adhesions                                                                      |
| 1     | Thin, avascular, spontaneously separating adhesions                               |
| 2     | Limited vascularization, adhesions separating by traction                         |
| 3     | Good vascularization, adhesions separating by dissection                          |

**Table 2: Definitions of the histopathological fibrosis score.**

| Grade | Definitions of the histopathological fibrosis scoring                              |
|-------|-----------------------------------------------------------------------------------|
| 0     | No fibrosis (no fibroblast and/or collagen fiber)                                  |
| 1     | Slight fibrosis—few fibroblast and/or collagen fibers                              |
| 2     | Median fibrosis (more fibroblast and/or collagen fibres)                           |
| 3     | Severe fibrosis (lots of fibroblasts and/or collagen fibers)                       |

---
paraffin, and 5 μm slices were cut and placed on a microscope slide. The tissue was stained with IHC stain used to identify the VEGF receptor. All evaluations were performed by an experienced pathologist who was blinded to the groups. The IHC staining severity and density of VEGF antibodies were evaluated in the areas where the stained cells were found in the adhesion tissues. The results were evaluated as follows: 0: no staining (negative), 1 = suspected, 2: mild, 3: moderate, and 4: strongly positive (Figures 2(a)–2(d)) [9].

2.8. Primary and Secondary Endpoints. The primary endpoint of this experimental study was the macroscopic adhesion score, which is the sum of the adhesion severity grading. The secondary endpoint was the microscopic brosis grading, extracted from the adhesion model area.

2.9. Statistical Analysis. The data were analyzed using SPSS 17.0 for Windows (SPSS Inc., Chicago, IL, USA). Percentages were compared with Student’s t-test, and the Pearson Chi-square test was used for nonparametric values. The P values given are 2-sided; P < 0.05 was considered to be the limit of significance.

3. Results

A total of 30 rats were operated. There was no wound dehiscence; three animals developed an incision hernia: 2 in Group II and one in Group III.

3.1. Adhesion Severity Score. Statistical comparison showed that the adhesion severity score in the bevacizumab group (Group III) differed significantly from the scores in Groups I (P < 0.001) and II (P < 0.001), while no difference was observed between Groups I and II (P = 0.72). The adhesion scores of the three groups and statistical analysis are summarized in Table 3. The statistical differences among all groups are also shown in Figure 3.
Figure 2: Immunohistochemistry for VEGF. No staining (a), suspected staining (b), moderate staining (c), and strong staining (d).

Figure 3: The bevacizumab group had a significantly lower adhesion grades.

Table 3: Macroscopic adhesion severity grades and mean group scores.

| Groups | Grade 0 | Grade 1 | Grade 2 | Grade 3 | Mean ± SD |
|--------|---------|---------|---------|---------|-----------|
| I      | 0       | 0       | 5       | 5       | 2.5 ± 0.52 |
| II     | 0       | 1       | 4       | 5       | 2.4 ± 0.69 |
| III    | 5       | 5       | 2       | 0       | 0.7 ± 0.82 |

I versus II: P = 0.72; I versus III; P < 0.001; II versus III; P < 0.001.

3.2 Histopathological Fibrosis Score. The fibrosis score in Group III was significantly less than that in Groups I (P < 0.001) and II (P < 0.001), while the fibrosis score did not differ significantly between Groups I and II (P = 0.55). The fibrosis scores and the statistical analysis are summarized in Table 4. The statistical differences among all groups are also shown in Figure 4.
Table 4: Microscopic histopathological fibrosis severity grades and mean group scores.

| Groups | Grade 0 | Grade 1 | Grade 2 | Grade 3 | Mean ± SD |
|--------|---------|---------|---------|---------|-----------|
| I      | 0       | 1       | 4       | 5       | 2.4 ± 0.69 |
| II     | 0       | 2       | 4       | 4       | 2.2 ± 0.78 |
| III    | 6       | 3       | 1       | 0       | 0.5 ± 0.70 |

I versus II: $P = 0.55$; I versus III: $P < 0.001$; II versus III: $P \leq 0.001$.

3.3. Immunohistochemical Staining for VEGF. The VEGF staining of the adhesion areas in Group III was significantly lower than that in Groups I ($P < 0.001$) and II ($P < 0.001$), while no significant difference was observed between Groups I and II ($P = 0.27$). The VEGF staining scores and the statistical analysis are summarized in Table 5. The statistical differences among all groups are also shown in Figure 5.

4. Discussion

Abdominal and pelvic adhesions are a major cause of morbidity, resulting in abdominal and pelvic pain, infertility, and small bowel obstruction. They are responsible for 30–41% of all intestinal obstructions [13]. Furthermore, pelvic adhesions resulting in mechanical blockage of the fallopian tubes are an important cause of infertility [14, 15]. Despite technological advances, postoperative peritoneal adhesions continue to constitute significant problems and remain a source of frustration for patients who have undergone laparotomy [16].

Various models have been developed to induce postoperative peritoneal adhesions experimentally, including local peritoneum excision, ischemic damage, the introduction of foreign objects into the peritoneal cavity, thermal damage, and bacterial contamination [4]. Any manipulation performed by the hands or surgical instruments during laparotomy constitutes mechanical trauma, which is the most frequent cause of postoperative peritoneal adhesions [4, 5]. We used a cecal abrasion model because it mimics the mechanical trauma that occurs during laparotomy.

Peritoneal adhesions are actually the result of normal wound healing, and postoperative peritoneal adhesions are seen most commonly within 7 to 15 days after surgery. Four similar, previously published studies were performed with species-specific antibodies to VEGF; in these studies, the test period (relaparotomy) was restricted to 7 and 30 days [1, 3, 9]. Our study was performed with a humanized antibody, in a species where abundant literature suggests a similarity in effect of bevacizumab in rats and humans. Our follow-up period was 7 days, and the adhesion maturation process can be affected by the reabsorbed circulating bevacizumab since it remains in circulation up to 6 weeks [1].

The search for an effective antiadhesion device has been continuing for decades. Several methods, materials, and agents have been assessed for their ability to prevent intra-abdominal peritoneal adhesions, including various surgical procedures, minimally invasive and laparoscopic techniques, pharmacological agents that target fibrin formation, and liquids, gels, and solids that can form a mechanical barrier between mesothelial surfaces [3–6].

Many animal and clinical studies have tested a variety agent to prevent intra-abdominal adhesion formation. These agents include dextran, honey, resveratrol, hyaluronic acid corticosteroid, saline, recombinant tissue plasminogen activators, aprotinin, atorvastatin, octreotide, heparin, nonsteroidal inflammatory drugs, tenoxicam, mitomycin, sildenafil, vitamin E, melatonin, and β-glucan [1, 3–7]. The intra-abdominal administration of antiadhesive barriers, such as a bioresorbable membrane consisting of sodium hyaluronate, polyethylene glycol, fibrin sealant, oxidized regenerated cellulose, expanded polytetrafluoroethylene, and carboxymethylcellulose, may reduce postoperative adhesions, as demonstrated by some animal models and clinical studies [1, 4–6]. Some of these agents have been shown to reduce the number and quality of adhesions, but none are
Vascular endothelial growth factor (VEGF) is a potent, angiogenic cytokine that is involved in the development of new blood vessels supplying areas of tissue damage/injury induced by surgery [21]. It is also involved directly in tissue restoration, including the early inflammatory responses and wound repair and remodeling via fibroblast function [22]. The central role of VEGF in facilitating the deposition of the fibrin-rich matrix necessary for subsequent cellular migration and proliferation would seem to make it a key agent in the formation of peritoneal adhesions [22]. Cahill et al. [23] showed that it is involved centrally in the early pathogenesis of postoperative adhesion formation and that mast cells seem to be responsible for the early surge in peritoneal VEGF levels after an operation. Bevacizumab is a recombinant humanized monoclonal antibody that binds all biologically active isoforms of VEGF and neutralizes the biological effects of VEGF, including endothelial cell mitogenesis, vascular permeability enhancement, and the promotion of angiogenesis. In mouse models, the administration of anti-VEGF antibodies was shown to block the growth of human tumor xenografts and reduce the size and number of metastases [18, 28].

VEGF seems to have important roles in the early formation of intra-abdominal postoperative adhesions. It is released into the peritoneal cavity from the injured vasculature after surgery. Bevacizumab neutralizes VEGF and blocks its signal transduction through both VEGFR-1 and VEGFR-2, as demonstrated by the inhibition of VEGF-induced cell proliferation and the modulation of peritoneal adhesions by neutralizing antibodies [29, 30]. The role of selective, antiangiogenic inhibitors in the treatment of neoplastic processes may be expanded to include antiadhesion strategies [29].

In our model, following the administration of bevacizumab, VEGF receptor levels and angiogenesis decreased in the excised adhesion surfaces and fibrin tissue, as shown in the histopathological examination. The application of bevacizumab reduced angiogenesis, which may have accompanied the reduction in adhesion formation. Bevacizumab reduced the VEGF receptor count in the injured tissue. Therefore, bevacizumab lowers the formation of adhesions by binding and blocking VEGF receptors. This result may open new horizons for this drug, which is currently prescribed for anticancer purposes, in preventing adhesion formation following laparotomy in high-risk patients.

We conclude that bevacizumab prevented postoperative adhesion formation experimentally. However, additional research and clinical trials are needed to investigate and validate its long-term effects and to establish a safe protocol for its use.

**Abbreviations**

VEGF: Vascular endothelial growth factor  
FGF-2: Fibroblast growth factor 2.

**Authors’ Contribution**

M. Basbug, N. Bulbuller, R. Ayten, and C. Camci performed the surgical procedure. S. Akbulut, M. Basbug, and Z. Arikanoglu contributed to writing the paper and review of the literature, as well as undertaking a comprehensive literature search. I. H. Ozercan provided the histopathological information.

**Conflict of Interests**

The authors declare that they have no conflict of interests.
Acknowledgments

The authors thank Ergun Oksuz from Family Medicine Unit of Baskent University for providing statistical analysis. This experimental study was presented as poster in the 18th International postgraduate course of the International association of surgeons, gastroenterologists, and oncologists (Hepatogastroenterology, October 2008; 55(Suppl1): A386, P454).

References

[1] D. Ignjatovic, K. Aasland, M. Pettersen et al., “Intra-abdominal administration of bevacizumab diminishes intraperitoneal adhesions,” American Journal of Surgery, vol. 200, no. 2, pp. 270–275, 2010.

[2] B. W. Hellebrekers, T. C. Trimbos-Kemper, L. Boesten et al., “Preoperative predictors of postsurgical adhesion formation and the prevention of adhesions with plasminogen activator (PAPA-study): results of a clinical pilot study,” Fertility and Sterility, vol. 91, no. 4, pp. 1204–1214, 2009.

[3] A. Emre, M. Akin, I. Isikgonul, O. Yuksel, A. Z. Anadol, and C. Cifter, “Comparison of intraperitoneal honey and sodium hyaluronate-carboxymethylcellulose (Seprafilm) for the prevention of postoperative intra-abdominal adhesions,” Clinics, vol. 64, no. 4, pp. 363–368, 2009.

[4] E. Aysan, H. Bektas, and A. Kaygusuz, “Efficacy of glycerol in preventing postoperative peritoneal adhesions,” Journal of Obstetrics and Gynaecology Research, vol. 36, no. 3, pp. 639–645, 2010.

[5] E. Aysan, H. Bektas, and F. Ersoz, “A new approach to postoperative peritoneal adhesions: prevention of peritoneal trauma by aloe vera gel,” European Journal of Obstetrics and Reproductive Biology, vol. 149, no. 2, pp. 195–198, 2010.

[6] E. Aysan, H. Bektas, and A. Kaygusuz, “Efficacy of octyl methoxycinnamate in preventing postoperative peritoneal adhesions: an experimental model,” Journal of Obstetrics and Gynaecology Research, vol. 35, no. 6, pp. 1102–1108, 2009.

[7] M. A. Lalountas, K. D. Ballas, C. Skouras et al., “Preventing intraperitoneal adhesions with atorvastatin and sodium hyaluronate/carboxymethylcellulose: a comparative study in rats,” American Journal of Surgery, vol. 200, no. 1, pp. 118–123, 2010.

[8] E. Ersoy, V. Ozturk, A. Yazgan, M. Ozdogan, and H. Gundogdu, “Comparison of the two types of bioresorbable barriers to prevent intra-abdominal adhesions in rats,” Journal of Gastrointestinal Surgery, vol. 13, no. 2, pp. 282–286, 2009.

[9] Y. Aritaş, A. Akcan, A. R. Erdoğan, H. Akgün, R. Saraymen, and H. Akylidiz, “Effects of melatonin and phospholipid on adhesion formation and correlation with vascular endothelial growth factor expression in rats,” Ulusal Travma ve Acil Cerrahi Dergisi, vol. 15, no. 5, pp. 416–422, 2009.

[10] A. N. Imudia, S. Kumar, G. M. Saed, and M. P. Diamond, “Pathogenesis of intra-abdominal and pelvic adhesion development,” Seminars in Reproductive Medicine, vol. 26, no. 4, pp. 289–297, 2008.

[11] R. A. Cahill and H. P. Redmond, “Cytokine orchestration in post-operative peritoneal adhesion formation,” World Journal of Gastroenterology, vol. 14, no. 31, pp. 4861–4866, 2008.

[12] D. M. Evans, K. McAree, D. P. Guyton, N. Hawkins, and K. Stakleff, “Dose dependency and wound healing aspects of the use of tissue plasminogen activator in the prevention of intra-abdominal adhesions,” American Journal of Surgery, vol. 165, no. 2, pp. 229–232, 1993.

[13] M. C. Parker, H. Ellis, B. J. Moran et al., “Postoperative adhesions: ten-year follow-up of 12,584 patients undergoing lower abdominal surgery,” Diseases of the Colon and Rectum, vol. 44, no. 6, pp. 822–829, 2001.

[14] D. Robertson, G. Lefebvre, N. Leyland et al., “Society of Obstetricians and Gynaecologists of Canada: adhesion prevention in gynaecological surgery,” Journal of Obstetrics and Gynaecology Canada, vol. 32, no. 6, pp. 598–608, 2010.

[15] A. Imai and N. Suzuki, “Topical non-barrier agents for postoperative adhesion prevention in animal models,” European Journal of Obstetrics Gynecology and Reproductive Biology, vol. 149, no. 2, pp. 131–135, 2010.

[16] H. Ellis, “Intraabdominal and postoperative peritoneal adhesions,” Journal of the American College of Surgeons, vol. 200, no. 5, pp. 643–644, 2005.

[17] H. Aksay, A. Akcan, E. Sozuer, C. Kucuk, N. Yilmaz, and K. Deniz, “The preventive effect of Met-RANTEs on postoperative intraperitoneal adhesion formation in the rat model,” Surgery, vol. 144, no. 3, pp. 404–409, 2008.

[18] N. Ferrara, K. J. Hillan, and W. Novotny, “Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy,” Biochemical and Biophysical Research Communications, vol. 333, no. 2, pp. 328–335, 2005.

[19] M. Toi, T. Matsumoto, and H. Bando, “Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications,” Lancet Oncology, vol. 2, no. 11, pp. 667–673, 2001.

[20] A. D. Thornton, P. Ravn, M. Winslet, and K. Chester, “Angiogenesis inhibition with bevacizumab and the surgical management of colorectal cancer,” British Journal of Surgery, vol. 93, no. 12, pp. 1456–1463, 2006.

[21] M. P. Diamond, E. El-Hammady, A. Munkarah, E. J. Bieber, and G. Saed, “Modulation of the expression of vascular endothelial growth factor in human fibroblasts,” Fertility and Sterility, vol. 83, no. 2, pp. 405–409, 2005.

[22] T. R. Howdieshell, D. Callaway, W. L. Webb et al., “Antibody neutralization of vascular endothelial growth factor inhibits wound granulation tissue formation,” Journal of Surgical Research, vol. 96, no. 2, pp. 173–182, 2001.

[23] R. A. Cahill, J. H. Wang, S. Soohkai, and H. P. Redmond, “Mast cells facilitate local VEGF release as an early event in the pathogenesis of postoperative peritoneal adhesions,” Surgery, vol. 140, no. 1, pp. 108–112, 2006.

[24] M. Yanagisawa, K. Fujimoto-Ouchi, K. Yokozu, Y. Yamashita, and K. Mori, “Antitumor activity of bevacizumab in combination with capcitabine and oxaliplatin in human colorectal cancer xenograft models,” Oncology Reports, vol. 22, no. 2, pp. 241–247, 2009.

[25] E. T. Pavlidis, K. D. Ballas, N. G. Symeonidis et al., “The effect of bevacizumab on colon anastomotic healing in rats,” International Journal of Colorectal Disease, vol. 25, no. 12, pp. 1465–1473, 2010.

[26] W. J. Kim, H. O. Jeong, and S. K. Chung, “The effect of bevacizumab on corneal neovascularization in rabbits,” Korean Journal of Ophthalmology, vol. 24, no. 4, pp. 230–236, 2010.

[27] V. Hsei, G. G. DeGuzman, A. Nixon, and J. Gaudreault, “Complexation of VEGF with bevacizumab decreases VEGF activity in vitro,” Journal of Ophthalmology, vol. 2009, Article ID 241726, 8 pages, 2009.

[28] N. Ferrara, K. J. Hillan, H. P. Gerber, and W. Novotny, “Discovery and development of bevacizumab, an anti-VEGF

Gastroenterology Research and Practice
antibody for treating cancer,” *Nature Reviews Drug Discovery*, vol. 3, no. 5, pp. 391–400, 2004.

[29] Y. Wang, D. Fei, M. Vanderlaan, and A. Song, “Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro,” *Angiogenesis*, vol. 7, no. 4, pp. 335–345, 2004.

[30] O. Moraloglu, H. Işık, S. Kiliç et al., “Effect of bevacizumab on postoperative adhesion formation in a rat uterine horn adhesion model and the correlation with vascular endothelial growth factor and Ki-67 immunopositivity,” *Fertility and Sterility*. In press.
Submit your manuscripts at
http://www.hindawi.com